| 08:30a | TRANSCRIPT : Novan, Inc., Q1 2022 Earnings Call, May 16, 2022 | CI |
| 08:30a | TRANSCRIPT : MediPharm Labs Corp., Q1 2022 Earnings Call, May 16, 2022 | CI |
| 08:30a | TRANSCRIPT : PolarityTE, Inc., Q1 2022 Earnings Call, May 16, 2022 | CI |
| 08:30a | TRANSCRIPT : Protalix BioTherapeutics, Inc., Q1 2022 Earnings Call, May 16, 2022 | CI |
| 08:20a | VALNEVA : Goldman Sachs reiterates its Buy rating | MD |
| 08:00a | TRANSCRIPT : Warby Parker Inc., Q1 2022 Earnings Call, May 16, 2022 | CI |
| 08:00a | TRANSCRIPT : Gracell Biotechnologies Inc., Q1 2022 Earnings Call, May 16, 2022 | CI |
| 07:45a | STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reaffirms its Neutral rating | MD |
| 07:37a | QIAGEN NV : Berenberg keeps its Buy rating | MD |
| 07:37a | CARL ZEISS MEDITEC AG : Gets a Buy rating from Deutsche Bank | MD |
| 07:27a | MERCK KGAA : Credit Suisse reiterates its Buy rating | MD |
| 06:43a | EU says no final decision taken on ending Valneva COVID vaccine contract | RE |
| 05:40a | CARL ZEISS MEDITEC AG : Buy rating from UBS | MD |
| 05:39a | Bristol Myers Squibb Trial of Carcinoma Treatments Fails to Meet Primary Endpoint | DJ |
| 04:54a | MERCK KGAA : Receives a Buy rating from JP Morgan | MD |
| 03:56a | NetScientific Shares Rise on Successful Completion of AstraZeneca Covid-19 Antibody Test | DJ |
| 03:26a | Tali Digital Limited Announces Changes in Registered Office | CI |
| 03:19a | Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan | CI |
| 03:17a | SARTORIUS VORZUEGE : UBS takes a positive view | MD |
| 03:00a | Nutex Health Announces Two New Fully Functional Micro Hospitals | CI |
| 02:30a | Pharnext Announces New Results from the Ongoing Open-Label Follow-Up Extension Study of PXT3003 | CI |
| 02:00a | Immunicum AB Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment | CI |
| 02:00a | Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies | CI |
| 02:00a | Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia | CI |
| 02:00a | Inventiva S.A. Secures A €50 Million Credit Facility from the European Investment Bank | CI |
| 01:30a | QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels | CI |
| 01:30a | Nicox S.A. Announces Executive Changes | CI |
| 05/16 | Innovent to Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology Annual Meeting | CI |
| 05/16 | 1,232,000 Equity Shares of Par Drugs and Chemicals Limited are subject to a Lock-Up Agreement Ending on 16-MAY-2022. | CI |
| 05/15 | Sanofi Says Phase 3 Study of Sarclisa Showed Longer Progression-Free Survival | DJ |
| 05/15 | Antengene Announces Commercial Availability of XPOVIO®, for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China | CI |
| 05/15 | Shionogi & Co. Announces Initiation of a Phase 2/3 Clinical Trial in Japanese Adolescents for the Covid-19 Recombinant Protein-Based Vaccine, S-268019 | CI |
| 05/15 | Elan Corporation Provides Dividend Guidance for the Year Ending December 31, 2022 | CI |
| 05/15 | Elan Corporation Provides Consolidated Earnings Guidance for the Year Ending Six Months Ending June 30, 2022 and Full Year Ending December 31, 2022 | CI |
| 05/15 | Fukuda Denshi Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended Mach 31, 2022 | CI |
| 05/15 | 4DMedical Limited Announces Clinical Trial Results Presented At Top US Lung Conference | CI |
| 05/15 | Mouwasat Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/15 | Middle East Healthcare Company Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/15 | Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting | CI |
| 05/14 | Wattanapat Hospital Trang Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/14 | Calliditas Therapeutics AB Launches an Online Patient Platform | CI |
| 05/14 | Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2022 | CI |
| 05/13 | OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/13 | Mycenax Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/13 | MedFirst Healthcare Services, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/13 | Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/13 | Garofalo Health Care S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/13 | INTAI Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/13 | Health & Life Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/13 | Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
